This site is intended for healthcare professionals
Drug information

Pancrex

OTC
Read time: 1 mins
Last updated: 17 Jun 2022

Summary of product characteristics


1. Name of the medicinal product

Pancrex V 125 mg hard capsules


2. Qualitative and quantitative composition

Each hard capsule contains 125 mg pancreatin to provide enzymatic activity per capsule not less than:

Free protease

Lipase

Amylase

160 BP units

2950 BP units

3300 BP units

For the full list of excipients, see section 6.1.


3. Pharmaceutical form

Hard capsule.

A white or buff coloured powder in clear hard gelatin capsules.


4.1. Therapeutic indications

Pancrex V is used to compensate for reduced intestinal enzyme activity in pancreatic deficiency states.

It is indicated for the treatment of fibrocystic disease of the pancreas (cystic fibrosis), chronic pancreatitis and pancreatic steatorrhoea following pancreatectomy. It may also be indicated following gastrectomy as an aid to digestion.


4.2. Posology and method of administration

Posology

These low dose capsules may be used when small amounts of Pancrex V are required, for example for neonates.

Dosage should be adjusted according to the needs of the individual patient and the amount of food consumed.

The following dosage scale provides a suitable basis for adjustment.

Paediatric population

Neonates: The contents of 1-2 capsules mixed with feeds.

Method of administration

Oral use.

The capsules should be taken with each feed or before a meal.

If the capsule contents are mixed with liquids or feeds the resulting mixture should not be allowed to stand for more than one hour prior to use.


4.3. Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.


4.4. Special warnings and precautions for use

It is possible that some irritation of the skin of the mouth may occur if capsules are chewed or the contents retained in the mouth. Irritation of the anus may also occur. A barrier cream may prevent this local irritation.

Allergic/asthmatic reactions have occasionally occurred on handling the capsule contents.


4.5. Interaction with other medicinal products and other forms of interaction

None known.


4.6. Fertility, pregnancy and lactation

Pancrex V should not be used in pregnancy and lactation unless clearly necessary but if required should be used in doses sufficient to provide adequate nutritional status.


4.7. Effects on ability to drive and use machines

Pancrex V has no or negligible influence on the ability to drive and use machines.


4.8. Undesirable effects

Rare cases of hyperuricosuria and hyperuricaemia have been reported when extremely high doses of pancreatin have been taken.

Strictures of the ileo-caecum and large bowel, and colitis, have been reported in children with cystic fibrosis taking high doses of pancreatic enzyme supplements. To date Pancrex and Pancrex V presentations have not been implicated in the development of colonic damage. However unusual abdominal symptoms or changes in abdominal symptoms should be reviewed to exclude the possibility of colonic damage especially if the patient is taking in excess of 10,000 units/kg/day of lipase.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellocard or search for MHRA Yellow Card in the Google Play or Apple App Store.


4.9. Overdose

None stated.


5.1. Pharmacodynamic properties

Pharmacotherapeutic group: Digestives, incl. enzymes, enzyme preparations, ATC code: A09AA02.

Mechanism of action

Pancreatin is derived from porcine pancreas and contains the enzymes, amylase, protease and lipase. The enzymes have the same actions as pancreatic juice and when administered to patients with pancreatic insufficiency improve the ability to metabolise starches, proteins and fats.


5.2. Pharmacokinetic properties

Pancreatin hydrolyses fats to glycerol and fatty acids, changes proteins into proteases and derived substances, and converts starch into dextrins and sugars.


5.3. Preclinical safety data

No relevant pre-clinical safety data has been generated.


6.1. List of excipients

Capsule shell

Gelatin

Capsule content

Aluminium oxide

Magnesium stearate

Microcrystalline cellulose


6.2. Incompatibilities

Not applicable.


6.3. Shelf life

3 years.


6.4. Special precautions for storage

Store in a refrigerator (2°C - 8°C).


6.5. Nature and contents of container

The drug product is contained in a polypropylene securitainer with low density polyethylene cap.

Securitainer: 300 and 500 capsules.

Not all pack sizes may be marketed.


6.6. Special precautions for disposal and other handling

No special requirements.


7. Marketing authorisation holder

Essential Pharmaceuticals Limited

Unit 7, Egham Business Village

Crabtree Road

Egham

Surrey TW20 8RB,

UK.


8. Marketing authorisation number(s)

PL 41094/0005


9. Date of first authorisation/renewal of the authorisation

Date of first authorisation: 13/11/1985

Date of latest renewal: 04/11/2003


10. Date of revision of the text

10/06/2022

4.1 Therapeutic indications

Pancrex V is used to compensate for reduced intestinal enzyme activity in pancreatic deficiency states.

It is indicated for the treatment of fibrocystic disease of the pancreas (cystic fibrosis), chronic pancreatitis and pancreatic steatorrhoea following pancreatectomy. It may also be indicated following gastrectomy as an aid to digestion.

4.2 Posology and method of administration

Posology

These low dose capsules may be used when small amounts of Pancrex V are required, for example for neonates.

Dosage should be adjusted according to the needs of the individual patient and the amount of food consumed.

The following dosage scale provides a suitable basis for adjustment.

Paediatric population

Neonates: The contents of 1-2 capsules mixed with feeds.

Method of administration

Oral use.

The capsules should be taken with each feed or before a meal.

If the capsule contents are mixed with liquids or feeds the resulting mixture should not be allowed to stand for more than one hour prior to use.

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

4.4 Special warnings and precautions for use

It is possible that some irritation of the skin of the mouth may occur if capsules are chewed or the contents retained in the mouth. Irritation of the anus may also occur. A barrier cream may prevent this local irritation.

Allergic/asthmatic reactions have occasionally occurred on handling the capsule contents.

4.5 Interaction with other medicinal products and other forms of interaction

None known.

4.6 Fertility, pregnancy and lactation

Pancrex V should not be used in pregnancy and lactation unless clearly necessary but if required should be used in doses sufficient to provide adequate nutritional status.

4.7 Effects on ability to drive and use machines

Pancrex V has no or negligible influence on the ability to drive and use machines.

4.8 Undesirable effects

Rare cases of hyperuricosuria and hyperuricaemia have been reported when extremely high doses of pancreatin have been taken.

Strictures of the ileo-caecum and large bowel, and colitis, have been reported in children with cystic fibrosis taking high doses of pancreatic enzyme supplements. To date Pancrex and Pancrex V presentations have not been implicated in the development of colonic damage. However unusual abdominal symptoms or changes in abdominal symptoms should be reviewed to exclude the possibility of colonic damage especially if the patient is taking in excess of 10,000 units/kg/day of lipase.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellocard or search for MHRA Yellow Card in the Google Play or Apple App Store.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

 

 

Disclaimer

The drug SPC information (indications, contra-indications, interactions, etc), has been developed in collaboration with eMC (www.medicines.org.uk/emc/). Medthority offers the whole library of SPC documents from eMC.

Medthority will not be held liable for explicit or implicit errors, or missing data.

Reporting of suspected adverse reactions 

Drug Licencing

Drugs appearing in this section are approved by UK Medicines & Healthcare Products Regulatory Agency (MHRA), & the European Medicines Agency (EMA).